Michael A Puskarich1,2, Cora McHugh3, Thomas L Flott3, Alla Karnovsky4,5, Alan E Jones6, Kathleen A Stringer3,7,8. 1. Department of Emergency Medicine, University of Minnesota, Minneapolis, Minnesota. 2. Department of Emergency Medicine, Hennepin County Medical Center, Minneapolis, Minnesota. 3. The NMR Metabolomics Laboratory and the Department of Clinical Pharmacy, College of Pharmacy, University of Michigan, Ann Arbor, Michigan. 4. Michigan Regional Comprehensive Metabolomics Resource Core ((MRC)), Ann Arbor, Michigan. 5. Department of Computational Medicine and Bioinformatics, School of Medicine, University of Michigan, Ann Arbor, Michigan. 6. Department of Emergency Medicine, University of Mississippi Medical Center, Jackson, Mississippi. 7. Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan. 8. Michigan Center for Integrative Research in Critical Care (MCIRCC), School of Medicine, University of Michigan, Ann Arbor, Michigan.
Abstract
BACKGROUND: Sepsis shifts cardiac metabolic fuel preference and this disruption may have implications for cardiovascular function. A greater understanding of the role of metabolism in the development and persistence of cardiovascular failure in sepsis could serve to identify novel pharmacotherapeutic approaches. METHODS: Secondary analysis of prospective quantitative proton nuclear magnetic resonance (1H-NMR) metabolomic data from patients enrolled in a phase II randomized control trial of L-carnitine in septic shock. Participants with a sequential organ failure assessment (SOFA) score of > = 5, lactate > = 2, and requiring vasopressor support for at least 4 h were eligible for enrollment. The independent prognostic value of metabolites to predict survival with shock resolution within 48 h and vasopressor free days were assessed. Concentrations of predictive metabolites were compared between participants with and without shock resolution at 48 h. RESULTS: Serum 1H-NMR metabolomics data from 228 patients were analyzed. Eighty-one (36%) patients met the primary outcome; 33 (14%) died prior to 48 h. The branched chain amino acids (BCAA), valine, leucine, and isoleucine were univariate predictors of the primary outcome after adjusting for multiple hypothesis testing, while valine remained significant after controlling for SOFA score. Similar results were observed when analyzed based on vasopressor free days, and persisted after controlling for confounding variables and excluding non-survivors. BCAA concentrations at 48 h significantly discriminated between those with shock resolution versus persistent shock. CONCLUSIONS: Among patients with septic shock, BCAA concentrations independently predict time to shock resolution. This study provides hypothesis generating data into the potential contribution of BCAAs to the pathophysiology of cardiovascular failure in sepsis, opening areas for future investigations.
BACKGROUND: Sepsis shifts cardiac metabolic fuel preference and this disruption may have implications for cardiovascular function. A greater understanding of the role of metabolism in the development and persistence of cardiovascular failure in sepsis could serve to identify novel pharmacotherapeutic approaches. METHODS: Secondary analysis of prospective quantitative proton nuclear magnetic resonance (1H-NMR) metabolomic data from patients enrolled in a phase II randomized control trial of L-carnitine in septic shock. Participants with a sequential organ failure assessment (SOFA) score of > = 5, lactate > = 2, and requiring vasopressor support for at least 4 h were eligible for enrollment. The independent prognostic value of metabolites to predict survival with shock resolution within 48 h and vasopressor free days were assessed. Concentrations of predictive metabolites were compared between participants with and without shock resolution at 48 h. RESULTS: Serum 1H-NMR metabolomics data from 228 patients were analyzed. Eighty-one (36%) patients met the primary outcome; 33 (14%) died prior to 48 h. The branched chain amino acids (BCAA), valine, leucine, and isoleucine were univariate predictors of the primary outcome after adjusting for multiple hypothesis testing, while valine remained significant after controlling for SOFA score. Similar results were observed when analyzed based on vasopressor free days, and persisted after controlling for confounding variables and excluding non-survivors. BCAA concentrations at 48 h significantly discriminated between those with shock resolution versus persistent shock. CONCLUSIONS: Among patients with septic shock, BCAA concentrations independently predict time to shock resolution. This study provides hypothesis generating data into the potential contribution of BCAAs to the pathophysiology of cardiovascular failure in sepsis, opening areas for future investigations.
Authors: Edward J Septimus; Craig M Coopersmith; Jessica Whittle; Caleb P Hale; Neil O Fishman; Thomas J Kim Journal: Clin Infect Dis Date: 2017-10-16 Impact factor: 9.079
Authors: Lonneke A van Vught; Maryse A Wiewel; Peter M C Klein Klouwenberg; Arie J Hoogendijk; Brendon P Scicluna; David S Y Ong; Olaf L Cremer; Janneke Horn; Marc M J Bonten; Marcus J Schultz; Tom van der Poll Journal: Crit Care Med Date: 2016-07 Impact factor: 7.598
Authors: Tao Li; Zhen Zhang; Stephen C Kolwicz; Lauren Abell; Nathan D Roe; Maengjo Kim; Bo Zhou; Yang Cao; Julia Ritterhoff; Haiwei Gu; Daniel Raftery; Haipeng Sun; Rong Tian Journal: Cell Metab Date: 2017-02-07 Impact factor: 27.287
Authors: Zudin A Puthucheary; Jaikitry Rawal; Mark McPhail; Bronwen Connolly; Gamunu Ratnayake; Pearl Chan; Nicholas S Hopkinson; Rahul Phadke; Rahul Padhke; Tracy Dew; Paul S Sidhu; Cristiana Velloso; John Seymour; Chibeza C Agley; Anna Selby; Marie Limb; Lindsay M Edwards; Kenneth Smith; Anthea Rowlerson; Michael John Rennie; John Moxham; Stephen D R Harridge; Nicholas Hart; Hugh E Montgomery Journal: JAMA Date: 2013-10-16 Impact factor: 56.272
Authors: Theodore S Jennaro; Elizabeth M Viglianti; Nicholas E Ingraham; Alan E Jones; Kathleen A Stringer; Michael A Puskarich Journal: J Clin Med Date: 2022-01-26 Impact factor: 4.241
Authors: Michael A Puskarich; Theodore S Jennaro; Christopher E Gillies; Charles R Evans; Alla Karnovsky; Cora E McHugh; Thomas L Flott; Alan E Jones; Kathleen A Stringer Journal: Clin Transl Sci Date: 2021-07-03 Impact factor: 4.689